A clinical pharmacological evidence-based analytical research study on the clinical pharmacokinetic dose-dependent correlation of oral haematinics with the obstetric and gynaecological global anaemic patients’ recovery rate

Moumita Hazra

doi:10.18203/2319-2003.ijbcp20223351

Authors

Moumita Hazra Department of Pharmacology, Narayana Medical College, Narayana Hospitals, Nellore, Andhra Pradesh, India Department of Pharmacology, Mamata Medical College, Mamata Hospitals, Khammam, Telangana, India Department of Pharmacology, J. J. M. Medical College and Hospitals, Bapuji Hospital, Chigateri General Hospital, Davangere, Karnataka, India Department of Clinical Pharmacology, Hazra Nursing Home, Hazra Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Polyclinic and Diagnostic Centre, Howrah, West Bengal, India Hazra Nursing Home, Hazra Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Academic Centre, Dr. Moumita Hazra’s Educational Centre, Howrah, West Bengal, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20223351

Keywords:

Oral haematinics, Drug dose, Patient recovery rate, Clinical pharmacokinetics, Clinical pharmacology, Evidence-based medicine

Abstract

Background: The goal of iron therapy is to repair the haemoglobin deficit and replenish storage iron. Oral haematinics are the treatment of choice, due to their higher effectiveness, higher safety, higher ease of administration, higher patient compliance, better accessibility, no occurrence of nosocomial infections and lower cost. This analytical evidence-based clinical research was conducted for the molecular pharmacokinetic study of the pharmacological response and adherence of the patients to oral haematinics, in global tertiary medical care centres.

Methods: 100 anaemic patients, who were treated for moderate iron-deficiency anaemia, were prescribed oral haematinics, such as, ferrous ascorbate, ferrous sulphate, ferrous fumarate and ferric ammonium citrate, containing 60 mg of elemental iron, once to thrice daily, with or after meals, according to the progress of the disease, treatment regimen scheduling, occurrence or non-occurrence of adverse drug reactions and prognosis of the patient. The pharmacokinetic dose-dependent percentage recovery rate of the patients on 1st (30th day), 2nd (60th day) and 3rd (90th day) months and follow-up (105th day) visits, was finally deduced from the patients’ recovery features of symptoms and signs, and the confirmatory laboratory investigations recordings, with the efficacy and safety evaluation findings.

Results: During the oral haematinics treatment, the pharmacokinetic dose-dependent percentage recovery rate of the patients was 29% on 30th day, 62% on 60th day, 93% on 90th day and 100% on 105th day of treatment.

Conclusions: All the oral haematinics treated global anaemic patients had shown 100% recovery rate in tertiary medical care centres.

Metrics

Metrics Loading ...

Author Biography

Moumita Hazra, Department of Pharmacology, Narayana Medical College, Narayana Hospitals, Nellore, Andhra Pradesh, India Department of Pharmacology, Mamata Medical College, Mamata Hospitals, Khammam, Telangana, India Department of Pharmacology, J. J. M. Medical College and Hospitals, Bapuji Hospital, Chigateri General Hospital, Davangere, Karnataka, India Department of Clinical Pharmacology, Hazra Nursing Home, Hazra Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Polyclinic and Diagnostic Centre, Howrah, West Bengal, India Hazra Nursing Home, Hazra Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Academic Centre, Dr. Moumita Hazra’s Educational Centre, Howrah, West Bengal, India

1Associate Professor, Head of Department In Charge, Department of Pharmacology, Mamata Medical College and Hospitals, Telangana, India;
2Medical Director, Consultant Multi-Specialist Clinical Pharmacological Physician, Consultant Clinical Pathologist, Medical Superintendent, Principal, Medical Academics and Clinical Research Director, Dr. Moumita Hazra’s Polyclinic And Diagnostic Centre, Hazra Nursing Home, Hazra Polyclinic And Diagnostic Centre, Dr. Moumita Hazra’s Academic Centre, Dr. Moumita Hazra’s Educational Centre, West Bengal, India, World;
3Consultant Pathologist, Laboratory Supervisor, Mahuya Diagnostic Centre and Doctors’ Chamber, West Bengal, India.

References

Hazra M. A pharmacotherapeutic study of prescription patterns, efficacy and safety of oral haematinics among the anaemic women population, in rural India. J Evid Based Med Healthc. 2019;6(38):2349-570.

Hazra M. A study on the aspects of pharmacoepidemiology and pharmacohaemovigilance of ferrous ascorbate, ferrous fumarate, ferrous sulphate and ferric ammonium citrate, among the rural anaemic women, in the Indian spectrum. Int J Basic Clin Pharmacol. 2019;8:2751-8.

Hazra M. A clinical pharmacological study of quantitative specific symptomatology in global anaemic patients, and pharmacovigilance evaluation of ferrous ascorbate supplements. Int J Curr Med Pharm Res. 2022;8(1):62-5.

Fitzsimons S, Yeo TJ, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. ESC Heart Fail. 2021;8:4572-83.

Huang LL, Lee D, Troster SM, Kent AB, Roberts MA, Macdougall IC, McMahon LP. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant. 2018;33:1628-35.

Kramer T, Wissmüller M, Natsina K, Gerhardt F, Freyhaus H, Dumitrescu D, et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study. J Cachexia Sarcopenia Muscle. 2021;12:1501-12.

Hansen R, Spangmose AN, Sommer VM, Holm C, Jorgensen FS, Krebs L, Pinborg A. Maternal first trimester iron status and its association with obstetric and perinatal outcomes. Arch Gynecol Obstet. 2022;305(1):35088196.